Date: 2014-02-05
Type of information: Grant
Company: SARTRIC consortium (BioVersys [Switzerland] SARomics Biostructures [Sweden]
Investors: European Eurostars Programme (EU)
Amount:
Funding type: grant
Planned used: The SARTRIC project addresses this deficiency by restoring antibiotic activity by blocking the transcriptional activation of resistance genes with small molecules and thus restoring the efficacy of already marketed drugs.
Others: * On February 5, 2014, BioVersys and SARomics Biostructures announced that they will collaborate and bring together their complementary expertise to tackle antimicrobial resistance in the SARTRIC project supported by the European initiative EUROSTARS. Antimicrobial resistance represents a major threat to public health worldwide and is far from being adequately addressed today, as evidenced by the low number of new products in clinical development. The SARTRIC project addresses this deficiency by restoring antibiotic activity by blocking the transcriptional activation of resistance genes with small molecules and thus restoring the efficacy of already marketed drugs. The two SME partners BioVersys AG and SARomics Biostructures will combine their technology modules, expertise and resources to drive the drug development process of initial hit molecules towards fully characterized lead molecules that qualify for preclinical testing. Part of the project will be financed by a Eurostars grant.
Therapeutic area:
